Sight Sciences Executive Compensation (FY25)
SGHT · Executive and director compensation, fiscal 2024 to 2025
The Sight Sciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 21, 2026Latest filing (DEF 14A): April 22, 2026
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
99 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Paul Badawi: $3,022,179 → $2,005,608 (33.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Sight Sciences' chief executive and what were they paid?
Total compensation for Paul Badawi, President and Chief Executive Officer, came to $2,005,608 in fiscal 2025. Badawi's total moved 33.6% lower from the $3,022,179 reported for fiscal 2024.
Which companies are in Sight Sciences' peer group?
The disclosed peer group names AxoGen, CareDx, ClearPoint Neuro, CVRx and iRadimed Corporation, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Badawi President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Alison Bauerlein Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jeremy Hayden Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Badawi President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Alison Bauerlein Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | — not reconciled |
Matthew Link Chief Commercial Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Jeremy Hayden Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Paul Badawi | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Jeremy Hayden | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Alison Bauerlein | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Gerhard Burbach | ◇ | ◇ | — | — | — | — | ◇ |
Staffan Encrantz Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Donald Zurbay | ◇ | ◇ | — | — | — | — | ◇ |
Catherine Mazzacco | ◇ | ◇ | — | — | — | — | ◇ |
Tamara Fountain, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Erica Rogers | ◇ | ◇ | — | — | — | — | ◇ |
Brenda Becker | ◇ | ◇ | — | — | — | — | ◇ |
David Badawi, M.D and Paul Badawi served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: We have adopted Stock Ownership Guidelines applicable to our executive officers and non-employee directors that ensure the interests of our executive officers and directors are aligned with those of our stockholders.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- AxoGen AXGN
- CareDx CDNA
- ClearPoint Neuro symbol not shown
- CVRx CVRX
- iRadimed Corporation IRMD
- NeuroPace symbol not shown
- OrthoPediatrics KIDS
- Pulse Biosciences PLSE
- RxSight RXST
- Senseonics Holdings SENS
- Si-BONE SIBN
- TELA Bio symbol not shown
- Treace Medical Concepts TMCI
- Zynex ZYXI
What this page does not include
Everything above is a fact Sight Sciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Sight Sciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
99 figures on this page, cited to the filing that reported them.
99 cited to the filing
Documents cited
- 0001140361-26-0161382025 Summary Compensation Table · DIRECTOR COMPENSATION · Outstanding Equity Awards at 2024 Fiscal Year-End
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Sight Sciences executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/SGHT (accessed 2026).
Short form: data: Velarion
The Sight Sciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Sight Sciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Sight Sciences discloses
The companies named in SGHT's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}